Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023296 · ClinicalTrials.gov registry record · Phase 1
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
A Phase 1 study of Pulmonary Hypertension and Sickle Cell Anemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 2
- Study locations
NCT00023296: Completed Phase 1 study of Pulmonary Hypertension and Sickle Cell Anemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00023296 is a Phase 1 study of Pulmonary Hypertension and Sickle Cell Anemia that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 59 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023296, a Phase 1 study of Pulmonary Hypertension and Sickle Cell Anemia, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will test whether inhaling nitric oxide (NO) gas mixed with room air can improve pulmonary hypertension (high blood pressure in the lungs) in patients with sickle cell anemia. Patients with sickle cell disease 18 years of age or older may be eligible to participate in one or more parts of this three-stage study, as follows: Stage 1 Patients undergo the following tests to determine the cause of their pulmonary hypertension: blood tests; echocardiogram (heart ultrasound); asthma test; oxygen breathing study with measurement of arterial blood oxygen levels; chest X-ray; lung scans; MRI of the heart; 6-minute walk test; night-time oxygen measurement while sleeping; and exercise studies. Stage 2 Patients have a detailed MRI evaluation of the heart and are admitted to the NIH Clinical Center intensive care unit (ICU) for the following test: A plastic tube is placed in a vein in the patient's arm and another tube is placed in a deeper neck or leg vein. A third tube is inserted through the vein into the heart and the lung artery to measure blood pressures in the heart and lungs directly. Following baseline measurements, three medications (inhaled oxygen, infused prostaglandin, and inhaled NO) are delivered for 2 hours each, separated by a 30-minute washout period. A small blood sample is drawn during the NO administration. Patients who cannot be treated with nitric oxide or for whom the treatment does not work may receive monthly exchange transfusions for 3 months. For this procedure, 3 to 5 five units of the patient's blood is removed and replaced with 3 to 5 units that do not have sickle hemoglobin. Some patients who do not respond to NO or exchange transfusions may receive an alternative therapy, such as oxygen, prostacyclin, L-arginine, bosentan or sidenafil. Stage 3 Patients remain in the ICU with catheters in place for another 24 hours. During this time they breathe NO. Lung pressures are measured every 4 hours and blood is drawn every 8 hours. They
Conditions Studied
Interventions
- DRUG Nitric Oxide
- DEVICE INO Pulse - NO Delivery System
Study Locations (2)
Maryland
- Suburban Hospital - Bethesda
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2001-07-27 |
| Est. Completion | 2015-11-09 |
| Phase | Phase 1 |
What the finished NCT00023296 record still lists
NCT00023296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Nitric Oxide is the first listed.
NCT00023296 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00023296 about?
NCT00023296 is a clinical study titled "Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension". This study will test whether inhaling nitric oxide (NO) gas mixed with room air can improve pulmonary hypertension (high blood pressure in the lungs) in patients with sickle cell anemia. Patients with sickle cell disease 18 years of age or older may be eligible to participate in one or more parts o...
What is the current status of trial NCT00023296?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2001-07-27. Estimated completion is 2015-11-09.
What conditions does trial NCT00023296 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Sickle Cell Anemia.
What interventions are being tested in trial NCT00023296?
The interventions under investigation include: Nitric Oxide (DRUG), INO Pulse - NO Delivery System (DEVICE).
Who is sponsoring clinical trial NCT00023296?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00023296 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00023296's enrollment target sits among peer trials
59 38th of 72 higher than 35 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
Feasibility of Semaglutide in Advanced Lung Disease
RECRUITING · Phase 1
-
Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension
RECRUITING · Phase 1
-
Effect of Bosentan on Exercise Capacity at High Altitude
COMPLETED · Phase 1
-
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
COMPLETED · Phase 1
-
Iloprost Effects on Gas Exchange and Pulmonary Mechanics
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI